Australian Government
Department of Health and Aged Care
Office of the Gene Technology Regulator

NOTIFICATION OF APPLICATION

Receipt of licence application from Intervet Australia Pty Ltd for commercial supply of a live attenuated vaccine containing canine distemper virus and a genetically modified canine parvovirus (Nobivac Puppy DP Plus) for dogs

The Office of the Gene Technology Regulator (OGTR) has received a licence application (DIR 202) from Intervet Australia Pty Ltd. A summary of the application and a Questions and Answers document is posted on our website (search for DIR 202).

Intervet Australia Pty Ltd is seeking approval for the import, transport, storage, supply to veterinary clinics and disposal of a live attenuated vaccine containing canine distemper virus and a genetically modified (GM) canine parvovirus (known as Nobivac Puppy DP Plus) as part of its commercial supply of a vaccine for dogs.

The OGTR is preparing a Risk Assessment and Risk Management Plan (RARMP) for the application. The RARMP will be prepared taking into account advice received from a broad range of experts, agencies and authorities, and relevant local councils, as specified in the *Gene Technology Act 2000*. This is expected to be released for public comment and advice from experts, agencies and authorities in **late April 2024.** There will be at least 30 days for submission of comments.

If you have any questions or would like to receive a copy of the application or the summary, please contact the OGTR and quote the reference number DIR 202.

Office of the Gene Technology Regulator MDP 54 GPO Box 9848 CANBERRA ACT 2601
Telephone: 1800 181 030 E-mail: ogtr@health.gov.au
OGTR website

Dr Raj Bhula
Gene Technology Regulator
10 January 2024